Hollencrest Capital Management Acquires 8,921 Shares of Johnson & Johnson $JNJ

Hollencrest Capital Management boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 142.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,204 shares of the company’s stock after buying an additional 8,921 shares during the quarter. Hollencrest Capital Management’s holdings in Johnson & Johnson were worth $3,716,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 21.6% in the first quarter. Meeder Asset Management Inc. now owns 144,080 shares of the company’s stock worth $35,219,000 after acquiring an additional 25,604 shares during the period. Meeder Advisory Services Inc. grew its position in Johnson & Johnson by 8.3% during the first quarter. Meeder Advisory Services Inc. now owns 63,813 shares of the company’s stock valued at $15,598,000 after buying an additional 4,916 shares during the period. Scarborough Advisors LLC purchased a new stake in Johnson & Johnson during the first quarter valued at approximately $241,000. Parallel Advisors LLC raised its position in Johnson & Johnson by 1.2% in the first quarter. Parallel Advisors LLC now owns 80,406 shares of the company’s stock worth $19,655,000 after acquiring an additional 966 shares during the period. Finally, Resolute Wealth Strategies LLC raised its position in Johnson & Johnson by 6.1% in the first quarter. Resolute Wealth Strategies LLC now owns 2,778 shares of the company’s stock worth $679,000 after acquiring an additional 159 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on JNJ. Bank of America upped their price objective on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research note on Friday, July 10th. Johnson Rice upgraded Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 target price on the stock in a research report on Thursday. Guggenheim restated a “buy” rating and issued a $270.00 price target on shares of Johnson & Johnson in a research report on Friday. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective on the stock in a research note on Wednesday, May 13th. Finally, TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $265.30.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J’s robust Q2 performance beat estimates for both earnings and revenue, prompting the company to raise its 2026 outlook and reinforcing confidence in its core pharmaceuticals and MedTech businesses. Article: Should You Buy, Sell or Hold J&J’s Stock Post a Robust Q2 Performance?
• Positive Sentiment: New MedTech developments, including an acquisition in spine technologies and FDA approval for a heart-device platform, add to J&J’s growth story and expand its medical device portfolio. Article: Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device
• Positive Sentiment: Several articles framed J&J as a long-term defensive holding, citing its diversified healthcare footprint, AAA-like balance sheet strength, and 64-year dividend growth streak, which can support investor demand during market volatility. Article: Why Johnson & Johnson Is a Stock You Can Own Forever

Johnson & Johnson Trading Down 1.7%

JNJ opened at $248.83 on Tuesday. The stock has a 50-day moving average of $240.37 and a 200 day moving average of $235.11. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12 month low of $162.78 and a 12 month high of $269.43. The firm has a market cap of $598.99 billion, a P/E ratio of 28.83, a P/E/G ratio of 2.39 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.68 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.